MOTs-C is a 16-amino-acid peptide encoded inside mitochondrial DNA rather than the regular genome, discovered in 2015. In animal studies it activates AMPK signalling, increases glucose uptake in muscle, and improves insulin sensitivity. It's often called a mitochondrial-derived peptide, the first one formally identified.

Is MOTs-C an exercise mimetic?

The exercise-mimetic label comes from mouse studies showing better running endurance and metabolic flexibility. Mice on a treadmill aren't the same as a human exercise programme. The closest human study measured MOTs-c levels rising in active men under heat stress, without any peptide injection, so it's tracking the pathway, not testing the therapy.

Is MOTs-C approved by the FDA?

No. MOTs-C isn't FDA-approved for any use. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended inclusion of MOTs-C on the 503A Bulk Drug Substances List, the list that covers pharmacy compounding. The uses put to the committee were obesity and osteoporosis. That's an advisory vote, not an approval, and FDA final action is pending.

Does MOTs-C reverse aging?

No good evidence backs that framing yet. The mouse data on metabolic markers and exercise capacity is real, but none of it has been shown to reverse aging, and there's no controlled human trial with a functional endpoint testing that claim. What exists is animal-model signal, not a demonstrated human effect.

MOTS-c — Wolverine Health — independent peptide journalism

How it works

Encoded in mitochondrial DNA — not nuclear DNA. That's unusual. It's the first peptide shown to have a mitochondrial genetic origin with systemic metabolic effects. Mouse models show it shifts metabolism toward fat burning and makes cells respond better to insulin — effects that look a lot like what exercise does. Human circulating levels decline with age and metabolic disease. The exercise-mimetic angle is what drives interest. The human evidence base is observational — what we know is that the levels change; what we don't know is whether supplementing them does what it does in mice.

FDA status: No FDA approval. On July 23, 2026, PCAC recommended inclusion of MOTS-c on the 503A Bulk Drug Substances List. FDA final action is pending.
WADA status: Permitted in sport
Route: subcutaneous injection

Key studies

A mitochondrial derived peptide MOTS-c promotes metabolic homeostasis — Lee et al. (2015), Cell Metabolism

MOTS-c, encoded within the mitochondrial 12S rRNA, promotes metabolic homeostasis by regulating glucose uptake and fatty acid metabolism, with circulating levels declining with age in both mice and humans.

Frequently asked

What is MOTs-C?
MOTs-C is a 16-amino-acid peptide encoded inside mitochondrial DNA rather than the regular genome, discovered in 2015. In animal studies it activates AMPK signalling, increases glucose uptake in muscle, and improves insulin sensitivity. It's often called a mitochondrial-derived peptide, the first one formally identified.
Is MOTs-C an exercise mimetic?
The exercise-mimetic label comes from mouse studies showing better running endurance and metabolic flexibility. Mice on a treadmill aren't the same as a human exercise programme. The closest human study measured MOTs-c levels rising in active men under heat stress, without any peptide injection, so it's tracking the pathway, not testing the therapy.
Is MOTs-C approved by the FDA?
No. MOTs-C isn't FDA-approved for any use. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended inclusion of MOTs-C on the 503A Bulk Drug Substances List, the list that covers pharmacy compounding. The uses put to the committee were obesity and osteoporosis. That's an advisory vote, not an approval, and FDA final action is pending.
Does MOTs-C reverse aging?
No good evidence backs that framing yet. The mouse data on metabolic markers and exercise capacity is real, but none of it has been shown to reverse aging, and there's no controlled human trial with a functional endpoint testing that claim. What exists is animal-model signal, not a demonstrated human effect.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on MOTS-c

What is PCAC? The FDA committee that reviews peptides for compounding

PCAC is the FDA advisory committee that reviews which raw ingredients compounding pharmacies may use. Here is what it does and what its votes mean.

503B outsourcing pharmacies and compounded peptides: the regulatory gap that still matters

Section 503B outsourcing facilities are the higher-volume, FDA-inspected cousin of the corner compounding pharmacy. The 503B Bulks List is its own regulatory pipeline — and it changes what an actual peptide supply chain looks like when one opens.

The PCAC review happened July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decided which of seven peptides US compounding pharmacies may eventually dispense by prescription. The recommendation is not an approval, the docket is not all the peptides, and the framing the forums used going in was mostly wrong.

MOTS-c vs Epitalon: two different bets on ageing slower

WADA

MOTS-c and Epitalon are two very different longevity bets — one on your metabolism, one on the clock inside your cells. Here is what each could do for you, which angle fits your goal, and how far the human proof goes on both.

Mitochondrial-derived peptides: the signals your engines stop sending

Your mitochondria don't just make energy — they send hormone-like signals that tell the body how to run, and the supply fades with age. Mitochondrial-derived peptides are that family. Here's what the class could do, how far proof goes, and where its most-studied member sits in July's FDA review.

MOTS-c: the exercise signal written into your mitochondria

MOTS-c is a tiny peptide your mitochondria release when you train — a signal that tells your body to handle fuel and hold onto strength like a younger one. The early science is genuinely exciting. Here is what it could do for you, and how far the human proof actually goes.

MOTS-c: the newest peptide in the longevity conversation

MOTS-c is a tiny peptide your mitochondria make to help the body handle fuel and hold onto strength — and the level falls with age. Here's the plain-English tour: what it is, what the early science says it might do, and where the July 2026 FDA review just put it.